gnbt - momento da verdade
AC Investor Blog Escreveu:Olha que se calhar o Pedro ainda se vai rir no fim..... a empresa até tem um bom produto, daí que caso pinte, não sei não, pode voar..... Por acaso hoje antes do arranque, quando ela cotava ainda 0.216 eu alertei os meus leitores do twitter para um invulgar volume no titulo. E é um facto que o volume foi mesmo um sinal de compradores anunciados. Para quem ainda segue o titulo, fiz uma análise no blog mais descritiva.
Obrigado pelo apoio AC!
Rir é uma boa terapia! Faz bem à saúde!
Um abraço
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Olha que se calhar o Pedro ainda se vai rir no fim..... a empresa até tem um bom produto, daí que caso pinte, não sei não, pode voar..... Por acaso hoje antes do arranque, quando ela cotava ainda 0.216 eu alertei os meus leitores do twitter para um invulgar volume no titulo. E é um facto que o volume foi mesmo um sinal de compradores anunciados. Para quem ainda segue o titulo, fiz uma análise no blog mais descritiva.
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Generex Schedules Press Conference & Investor Call for March 30th to Discuss Management's Strategic Development Plan for Future Growth
Soon after his appointment as Interim President & Chief Executive Officer, Mark Fletcher and the Generex management team began conducting an in-depth review of the Company's operations and scientific initiatives in an effort to further the development of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, and the Antigen Express AE37 immunotherapeutic cancer vaccine platform, streamline operations, and maximize the value of the substantial intellectual properties currently held by the Company. After completing that review, management has developed a strategic plan to further the Company's science with a view to creating the greatest likelihood for commercial successes as well as attain the highest possible long-term value for Generex and its stockholders.
Management will discuss this plan along with the current status of its various drug development initiatives on March 30, 2011 at a press conference in New York City and an investor call. The details for attending the press conference and participation in the investor call via webcast or telephonically will be provided in the very near future.
Soon after his appointment as Interim President & Chief Executive Officer, Mark Fletcher and the Generex management team began conducting an in-depth review of the Company's operations and scientific initiatives in an effort to further the development of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, and the Antigen Express AE37 immunotherapeutic cancer vaccine platform, streamline operations, and maximize the value of the substantial intellectual properties currently held by the Company. After completing that review, management has developed a strategic plan to further the Company's science with a view to creating the greatest likelihood for commercial successes as well as attain the highest possible long-term value for Generex and its stockholders.
Management will discuss this plan along with the current status of its various drug development initiatives on March 30, 2011 at a press conference in New York City and an investor call. The details for attending the press conference and participation in the investor call via webcast or telephonically will be provided in the very near future.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
AC Investor Blog Escreveu:Pedro isto é para ti.... HEB um papel a ter em mente...
XMRV & AMPLIGEN, Hunter-Hopkins ME-letter March 2011 20-Mar-11 12:44 am
A Report from the 9th Hemispherx Biopharma Investigators Meeting
March 3-6, 2011· Gene Sequencing in Persons with CFS
· XMRV Subset Analysis and Ampligen Treatment
· What Is Ampligen?
Dr. Lapp:
Gene Sequencing in Persons with CFS
Wendy Fallick, our research coordinator, and I have just returned from the 9th Investigators Meeting sponsored by Hemispherx Biopharma, makers of Ampligen and Alferon. This was perhaps the most exciting of these meetings that I have attended, and I suspect that information relayed this past week to us will change the field of medicine forever. I want to share that information with you.
Subset Analysis and Ampligen Treatment
Dr. David Strayer, Medical Director at Hemipsherx Biopharma, described a retrospective study of the response to Ampligen in subjects who were positive or negative for XMRV. XMRV was tested at VIP Labs, which is associated with the Whittemore-Peterson Institute, and used similar techniques as those employed by Dr. Mikovits at the WPI.
In one study, serum from 208 subjects from a previous double blind placebo controlled Ampligen study were analyzed for XMRV. About one third were positive for the virus and two-thirds were not. Activity monitoring demonstrated less activity in XMRV+ subjects. That is, they were less active and presumably more ill.
Specifically, the improvement in exercise ability was monitored in these subjects. More improvement was measured inXMRV+ subjects than in XMRV-subjects. The table below describes the percentage of subjects who obtained at least 25% improvement in treadmill exercise duration at week 40 of treatment, as related to XMRV serology:
XMRV StatusImproved on AmpligenImproved with placeboDifference (AMP-PBO)
Pos (n=81)44.7%17.6%27.1%`
Neg (n=127)34.0%25.7%8.3%
Overall39%23%15.9%
Dr. Strayer concluded that there was a 70% greater than average exercise response in XMRV+ subjects, and a 40% lower response in those who were XMRV-.
Medication use was monitored in all of these subjects as well. 53% of XMRV+ subjects were able to reduce their use of symptomatic medications, while only 32% of XMRV- subjects were able to reduce medication use.
These data suggest that subjects who are XMRV+ have an edge in responding to Ampligen, and that Ampligen may be a treatment for CFS.
Strayer reported plans by Hemispherx to monitor this in the current cost recovery (AMP-511) program, and hopefully to generate another large double blind placebo-controlled crossover study.
Thanks AC!
Vou ler com calma!
Já agora AC, de vez em quando dá uma vista de olhos na Generex. Pode vir ai bomba....
Nos últimos meses a generex publicou vários artigos científicos sobre o AE37 e sobre o Oral Lyn nas principais revistas científicas mundiais (de maior índice de impacto). De tanto levar "pancada", não publiquei essas notícias aqui. Mas essa informação está dísponível online, é uma questão de procurar! Mas uma vez que quase nínguem acredita na gnbt, também não vale apena colocar aqui
.
O mais estranho é que da generex o silencio é total....
Continuo a bater a mesma tecla! para mim a generex vai ser o stock do ano de 2011.
Para o Ulisses não ficar chateado (e para justificar o meu interesse pela gnbt) deixo esta noticia publicado na Expert Review of Vaccines, Feb 2011, Vol. 10, No. 2, Pages 201-210.
Impact factor: 4.214 (2009) -
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
Linda C Benavides, Alan K Sears, Jeremy D Gates, Guy T Clifton, Kevin S Clive, Mark G Carmichael, Jarrod P Holmes, Elizabeth A Mittendorf, Sathibalan Ponniah, George E Peoples
Expert Review of Vaccines, Feb 2011, Vol. 10, No. 2, Pages 201-210.
We have performed multiple adjuvant clinical trials using immunogenic peptides from the HER2/neu protein (AE37/E75/GP2) plus (GM-CSF) given intradermally to breast cancer patients. Four trials were performed with similar dose-escalation design with increasing doses of peptide (AE37/E75/GP2) and varying amounts of GM-CSF. Dose reductions (DRs) were made for significant local and/or systemic toxicity by decreasing GM-CSF for subsequent inoculations. Ex vivo and in vivo immunologic responses were used to compare groups. Of 132 patients, 39 required DR (30 for robust local reactions [DR-L]). DR patients, particularly DR-L, had greater immune responses both ex vivo and in vivo. Postvaccine delayed-type hypersensitivity in DR-L patients compared with all others was larger for E75 (p = 0.001), AE37 (p = 0.077) and GP2 (p = 0.076). All three peptide vaccines were safe and well-tolerated. These findings have led to a clinically relevant optimal vaccine dosing strategy, which may be applicable to other peptide-based cancer vaccines.
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Pedro isto é para ti.... HEB um papel a ter em mente...
XMRV & AMPLIGEN, Hunter-Hopkins ME-letter March 2011 20-Mar-11 12:44 am
A Report from the 9th Hemispherx Biopharma Investigators Meeting
March 3-6, 2011· Gene Sequencing in Persons with CFS
· XMRV Subset Analysis and Ampligen Treatment
· What Is Ampligen?
Dr. Lapp:
Gene Sequencing in Persons with CFS
Wendy Fallick, our research coordinator, and I have just returned from the 9th Investigators Meeting sponsored by Hemispherx Biopharma, makers of Ampligen and Alferon. This was perhaps the most exciting of these meetings that I have attended, and I suspect that information relayed this past week to us will change the field of medicine forever. I want to share that information with you.
Subset Analysis and Ampligen Treatment
Dr. David Strayer, Medical Director at Hemipsherx Biopharma, described a retrospective study of the response to Ampligen in subjects who were positive or negative for XMRV. XMRV was tested at VIP Labs, which is associated with the Whittemore-Peterson Institute, and used similar techniques as those employed by Dr. Mikovits at the WPI.
In one study, serum from 208 subjects from a previous double blind placebo controlled Ampligen study were analyzed for XMRV. About one third were positive for the virus and two-thirds were not. Activity monitoring demonstrated less activity in XMRV+ subjects. That is, they were less active and presumably more ill.
Specifically, the improvement in exercise ability was monitored in these subjects. More improvement was measured inXMRV+ subjects than in XMRV-subjects. The table below describes the percentage of subjects who obtained at least 25% improvement in treadmill exercise duration at week 40 of treatment, as related to XMRV serology:
XMRV StatusImproved on AmpligenImproved with placeboDifference (AMP-PBO)
Pos (n=81)44.7%17.6%27.1%`
Neg (n=127)34.0%25.7%8.3%
Overall39%23%15.9%
Dr. Strayer concluded that there was a 70% greater than average exercise response in XMRV+ subjects, and a 40% lower response in those who were XMRV-.
Medication use was monitored in all of these subjects as well. 53% of XMRV+ subjects were able to reduce their use of symptomatic medications, while only 32% of XMRV- subjects were able to reduce medication use.
These data suggest that subjects who are XMRV+ have an edge in responding to Ampligen, and that Ampligen may be a treatment for CFS.
Strayer reported plans by Hemispherx to monitor this in the current cost recovery (AMP-511) program, and hopefully to generate another large double blind placebo-controlled crossover study.
XMRV & AMPLIGEN, Hunter-Hopkins ME-letter March 2011 20-Mar-11 12:44 am
A Report from the 9th Hemispherx Biopharma Investigators Meeting
March 3-6, 2011· Gene Sequencing in Persons with CFS
· XMRV Subset Analysis and Ampligen Treatment
· What Is Ampligen?
Dr. Lapp:
Gene Sequencing in Persons with CFS
Wendy Fallick, our research coordinator, and I have just returned from the 9th Investigators Meeting sponsored by Hemispherx Biopharma, makers of Ampligen and Alferon. This was perhaps the most exciting of these meetings that I have attended, and I suspect that information relayed this past week to us will change the field of medicine forever. I want to share that information with you.
Subset Analysis and Ampligen Treatment
Dr. David Strayer, Medical Director at Hemipsherx Biopharma, described a retrospective study of the response to Ampligen in subjects who were positive or negative for XMRV. XMRV was tested at VIP Labs, which is associated with the Whittemore-Peterson Institute, and used similar techniques as those employed by Dr. Mikovits at the WPI.
In one study, serum from 208 subjects from a previous double blind placebo controlled Ampligen study were analyzed for XMRV. About one third were positive for the virus and two-thirds were not. Activity monitoring demonstrated less activity in XMRV+ subjects. That is, they were less active and presumably more ill.
Specifically, the improvement in exercise ability was monitored in these subjects. More improvement was measured inXMRV+ subjects than in XMRV-subjects. The table below describes the percentage of subjects who obtained at least 25% improvement in treadmill exercise duration at week 40 of treatment, as related to XMRV serology:
XMRV StatusImproved on AmpligenImproved with placeboDifference (AMP-PBO)
Pos (n=81)44.7%17.6%27.1%`
Neg (n=127)34.0%25.7%8.3%
Overall39%23%15.9%
Dr. Strayer concluded that there was a 70% greater than average exercise response in XMRV+ subjects, and a 40% lower response in those who were XMRV-.
Medication use was monitored in all of these subjects as well. 53% of XMRV+ subjects were able to reduce their use of symptomatic medications, while only 32% of XMRV- subjects were able to reduce medication use.
These data suggest that subjects who are XMRV+ have an edge in responding to Ampligen, and that Ampligen may be a treatment for CFS.
Strayer reported plans by Hemispherx to monitor this in the current cost recovery (AMP-511) program, and hopefully to generate another large double blind placebo-controlled crossover study.
AC Investor Blog
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
www.ac-investor.blogspot.com -
Análises Técnicas de activos cotados em Wall Street. Os artigos do AC Investor podem também ser encontrados diariamente nos portais financeiros, Daily Markets, Benzinga, Minyanville, Solar Feeds e Wall Street Pit, sendo editor e contribuidor. Segue-me também no Twitter : http://twitter.com/#!/ACInvestorBlog e subscreve a minha newsletter.
-
- Mensagens: 4891
- Registado: 8/12/2007 23:01
- Localização: Vila Nova de Gaia
Acho que sim Pedro, eu tb ainda tenho umas, vendi mais de metade da carteira nos 0,32 e estou a ponderar comprar outra vez mais qq coizita.
Isto tanto o cantaro vai a fonte qie um dia acaba por partir...............mas que seja para cima!!!
Vai nos mantendo informados de noticias que vão surgindo, o Bigcharts tem tido pouca coisa da Generex
Abraço
Shevet
Isto tanto o cantaro vai a fonte qie um dia acaba por partir...............mas que seja para cima!!!
Vai nos mantendo informados de noticias que vão surgindo, o Bigcharts tem tido pouca coisa da Generex
Abraço
Shevet
Estás a sentir????
O 50 Cent, looooooool
O 50 Cent, looooooool
-
- Mensagens: 911
- Registado: 14/2/2006 15:32
- Localização: Caldeirada de Enguias
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
Drecksack Escreveu:pedro200 Escreveu:Atenção que brevemente podemos ter notícias da provável aprovação do oral lyn na india e do fim dos ensaios clinicos do oral lyn nos EUA!. Qualquer uma destas noticias pode fazer a generex disparar. Isto para não falar de uma provável parternship com uma grande farmaceútica.
e além disso ainda temos o AE37
Abraço,
O que é certo é que andas a repetir exactamente isto meses e meses e meses afim.
Tens razão!
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
pedro200 Escreveu:Atenção que brevemente podemos ter notícias da provável aprovação do oral lyn na india e do fim dos ensaios clinicos do oral lyn nos EUA!. Qualquer uma destas noticias pode fazer a generex disparar. Isto para não falar de uma provável parternship com uma grande farmaceútica.
e além disso ainda temos o AE37
Abraço,
O que é certo é que andas a repetir exactamente isto meses e meses e meses afim.
- Mensagens: 980
- Registado: 30/6/2008 20:42
- Localização: 1
Shevet Escreveu:eu nao ando a gostar nada da generex!! Com geito ainda avemos outra vez a 0,08usd
Quanto à CTIC acho que tem a ver com fusões/aquisições
Abraço
Shevet
Atenção que brevemente podemos ter notícias da provável aprovação do oral lyn na india e do fim dos ensaios clinicos do oral lyn nos EUA!. Qualquer uma destas noticias pode fazer a generex disparar. Isto para não falar de uma provável parternship com uma grande farmaceútica.
e além disso ainda temos o AE37
Abraço,
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Boas,
Repararam no comportamenento da CTIC nos últimos dias? Hoje, no pré-market já sobe fortemente....depois de quedas sucessivas, está a subir como um foguete...
Portanto, atenção à gnbt! um dia estas quedas vão terminar...
Go AE37 e Oral Lyn! Até hoje, todos os resultados dos ensaios clínicos têm sido positivos! E a cotação só desce....
Cumprimentos
Repararam no comportamenento da CTIC nos últimos dias? Hoje, no pré-market já sobe fortemente....depois de quedas sucessivas, está a subir como um foguete...
Portanto, atenção à gnbt! um dia estas quedas vão terminar...
Go AE37 e Oral Lyn! Até hoje, todos os resultados dos ensaios clínicos têm sido positivos! E a cotação só desce....
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
A GNBT apresenta resultados na próxima segunda-feira.
Upcoming Events
Date Event
7-Mar-11 Earnings announcement
http://finance.yahoo.com/q/ce?s=GNBT.OB+Company+Events
Upcoming Events
Date Event
7-Mar-11 Earnings announcement
http://finance.yahoo.com/q/ce?s=GNBT.OB+Company+Events
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ver: http://www.psi-cro.com/
PSI completed enrollment in a phase III study of a novel insulin formulation in patients with type I diabetes.
Ver: http://clinicaltrials.gov/ct2/show/NCT00668850
Sponsors and Collaborators
Generex Biotechnology Corp.OSMOS Clinical Research, Inc
PSI Pharma Support Intl
Nextrials, Inc.
eResearch Technology, Inc.
Hoffmann-La Roche
ACM Pivotal Global Central Laboratory
PSI completed enrollment in a phase III study of a novel insulin formulation in patients with type I diabetes.
Ver: http://clinicaltrials.gov/ct2/show/NCT00668850
Sponsors and Collaborators
Generex Biotechnology Corp.OSMOS Clinical Research, Inc
PSI Pharma Support Intl
Nextrials, Inc.
eResearch Technology, Inc.
Hoffmann-La Roche
ACM Pivotal Global Central Laboratory
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Ulisses Pereira Escreveu:Pedro, desculpa mas a acção não pára de cair há muitos meses. Isso é tudo menos acumulação. E o que continuamos a assistir neste tópico é um discurso de "agora é que vai ser".
Este tópico mostra bem os erros que muitos cometem e como a crença é algo demasiado perigoso nos mercados de capitais.
Um abraço,
Ulisses
Ulisses:
Tens toda a razão! A acção ao longo dos últimos meses não pará de cair.
O único motivo, pelo qual ainda continuo a colocar aqui posts (de vez em quando), deve-se ao facto de, apesar das quedas nos últimos meses, a generex em todas as noticias que divulgou, apresentou sempre resultados positivos para o Ae37 e Oral Lyn. Até pode acontecer que no futuro os resultados dos ensaios clínicos sejam desastrosos. Mas, já imaginaste na possibilidade de um ou os dois produtos chegarem ao mercado? O Ae37 ainda vai demorar, mas o Oral Lyn está na recta final da fase III.
Mas obrigado pela chamada de atenção.
Um abraço
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Pedro, desculpa mas a acção não pára de cair há muitos meses. Isso é tudo menos acumulação. E o que continuamos a assistir neste tópico é um discurso de "agora é que vai ser".
Este tópico mostra bem os erros que muitos cometem e como a crença é algo demasiado perigoso nos mercados de capitais.
Um abraço,
Ulisses
Este tópico mostra bem os erros que muitos cometem e como a crença é algo demasiado perigoso nos mercados de capitais.
Um abraço,
Ulisses
-
- Administrador Fórum
- Mensagens: 31013
- Registado: 29/10/2002 4:04
- Localização: Aveiro
pasil74 Escreveu:Generex Receives AE37 Immunotherapeutic Cancer Vaccine Patent
10:30 AM Eastern Standard Time, 02/03/2011 (MidnightTrader) -- Generex Biotechnology (GNBT.ob) announced today that its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, has received a Notice of Allowance from the United States Patent Office regarding its application for making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.
The company has received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform. This current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The new patent's term will extend through January 5, 2028.
AE37 is the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. According to the company, favorable results from this study have been reported previously.
Shares are up 0.43% to $0.231.
Price: 0.231, Change: +0.001, Percent Change: +0.43
(C) 2010 MidnightTrader, Inc. All rights reserved.
Não se passa nada
Boas!
melhor que essa noticia, são os dados que estão na página da FDA sobre o Oral Lyn:
http://clinicaltrials.gov/ct2/show/NCT00948493
"Expanded access is currently available for this treatment"
Cumprimentos
- Mensagens: 577
- Registado: 1/9/2009 10:52
- Localização: 7
Generex Receives AE37 Immunotherapeutic Cancer Vaccine Patent
10:30 AM Eastern Standard Time, 02/03/2011 (MidnightTrader) -- Generex Biotechnology (GNBT.ob) announced today that its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, has received a Notice of Allowance from the United States Patent Office regarding its application for making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.
The company has received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform. This current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The new patent's term will extend through January 5, 2028.
AE37 is the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. According to the company, favorable results from this study have been reported previously.
Shares are up 0.43% to $0.231.
Price: 0.231, Change: +0.001, Percent Change: +0.43
(C) 2010 MidnightTrader, Inc. All rights reserved.
Não se passa nada
10:30 AM Eastern Standard Time, 02/03/2011 (MidnightTrader) -- Generex Biotechnology (GNBT.ob) announced today that its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, has received a Notice of Allowance from the United States Patent Office regarding its application for making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.
The company has received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform. This current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The new patent's term will extend through January 5, 2028.
AE37 is the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. According to the company, favorable results from this study have been reported previously.
Shares are up 0.43% to $0.231.
Price: 0.231, Change: +0.001, Percent Change: +0.43
(C) 2010 MidnightTrader, Inc. All rights reserved.
Não se passa nada
- Mensagens: 331
- Registado: 7/12/2007 0:29
WORCESTER, Mass. , Feb. 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine. The Company has previously received allowances of broad claims surrounding its Ii-Key hybrid technology, which was used in the design of the AE37 vaccine platform. The current allowance strengthens independent composition of matter claims directed to the AE37 peptide. The full term of the new patent will extend through January 5, 2028 .
(Logo: http://photos.prnewswire.com/prnh/20110 ... 5057LOGO-b )
AE37 is currently the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. Favorable results from this study have been reported previously. This immunotherapeutic vaccine also has been tested in a Phase I study in patients with prostate cancer, which confirmed the safety and immunogenicity observed in the prior breast cancer study. In addition to breast and prostate cancer, many other types of cancer, such as lung, colon, stomach and bladder, also express the HER2 protein, which is the target for an AE37 stimulated immune response.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission , which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
(Logo: http://photos.prnewswire.com/prnh/20110 ... 5057LOGO-b )
AE37 is currently the subject of a randomized and controlled Phase II efficacy study in patients treated for breast cancer who are at high risk of recurrence. Favorable results from this study have been reported previously. This immunotherapeutic vaccine also has been tested in a Phase I study in patients with prostate cancer, which confirmed the safety and immunogenicity observed in the prior breast cancer study. In addition to breast and prostate cancer, many other types of cancer, such as lung, colon, stomach and bladder, also express the HER2 protein, which is the target for an AE37 stimulated immune response.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission , which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
- Mensagens: 331
- Registado: 7/12/2007 0:29
Quem está ligado:
Utilizadores a ver este Fórum: Google [Bot], niceboy e 183 visitantes